It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cardiac alternans have crucial importance in the onset of ventricular fibrillation. The early explanation for alternans development was the voltage-driven mechanism, where the action potential (AP) restitution steepness was considered as crucial determining factor. Recent results suggest that restitution slope is an inadequate predictor for alternans development, but several studies still claim the role of membrane potential as underlying mechanism of alternans. These controversial data indicate that the relationship of restitution and alternans development is not completely understood. APs were measured by conventional microelectrode technique from canine right ventricular papillary muscles. Ionic currents combined with fluorescent measurements were recorded by patch-clamp technique. APs combined with fluorescent measurements were monitored by sharp microelectrodes. Rapid pacing evoked restitution-independent AP duration (APD) alternans. When non-alternating AP voltage command was used, Ca2+i-transient (CaT) alternans were not observed. When alternating rectangular voltage pulses were applied, CaT alternans were proportional to ICaL amplitude alternans. Selective ICaL inhibition did not influence the fast phase of APD restitution. In this study we found that ICaL has minor contribution in shaping the fast phase of restitution curve suggesting that ICaL—if it plays important role in the alternans mechanism—could be an additional factor that attenuates the reliability of APD restitution slope to predict alternans.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Szeged, Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625)
2 ELKH-SZTE Research Group of Cardiovascular Pharmacology, Szeged, Hungary (GRID:grid.9008.1)
3 University of Debrecen, Department of Physiology, Faculty of Medicine, Debrecen, Hungary (GRID:grid.7122.6) (ISNI:0000 0001 1088 8582)
4 University of Debrecen, Department of Physiology, Faculty of Medicine, Debrecen, Hungary (GRID:grid.7122.6) (ISNI:0000 0001 1088 8582); University of Debrecen, Faculty of Pharmacy, Debrecen, Hungary (GRID:grid.7122.6) (ISNI:0000 0001 1088 8582)
5 University of Szeged, Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625); ELKH-SZTE Research Group of Cardiovascular Pharmacology, Szeged, Hungary (GRID:grid.9008.1)
6 University of Szeged, Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625); ELKH-SZTE Research Group of Cardiovascular Pharmacology, Szeged, Hungary (GRID:grid.9008.1); University of Szeged, Department of Pharmacology and Pharmacotherapy, Interdisciplinary Excellence Centre, Szeged, Hungary (GRID:grid.9008.1) (ISNI:0000 0001 1016 9625)